3-14-05

Express Mail No. EV335611902US

Fie

MAR 1 1 2005 19

TRANSMITTAL FORM

(To be used for all correspondence after initial filing)

Application Number	10/624,946		
Filing Date	July 21, 2003		
First Named Inventor	Jeffery R. Raymond		
Art Unit	1616		
Examiner Name	Barbara P. Badio, Ph.D.		
Attorney Docket No.	480117.407C1		

ENCLOSURES (check all that apply)					
Fee Transmitta Fee Attack Response to After Final Affidavits/ Extension of T Express Abanc Request Information Dis Statement; For Cited Reference Certified Copy Document(s) Response to M under 37 C.F.F. Response to M Parts/Incomple	declaration(s) ime Request donment sclosure rm PTO-1449 ces of Priority dissing Parts R. 1.52 or 1.53 dissing	Drawing(s) Request for Corrected Filing Receipt Licensing-related Papers Petition Petition to Convert to a Provisional Application Power of Attorney, Revocation, Change of Correspondence Address Declaration Statement under 37 CFR 3.73(b) Terminal Disclaimer Request for Refund CD, Number of CD(s) Landscape Table on C	g	After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Return Receipt Postcard Other Enclosure(s) (please identify below):	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT					
Firm Name		tual Property Law Group PLLC		Customer Number 00500	
Signature	Carol & Rota				
Printed Name Carol J. Roth					
Date	March 11, 20	05 Re	ı. No.	32,783	
CERTIFICATE OF TRANSMISSION/MAILING					
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.					
Signature	~~ 8	~~ Sent via Express Mail ~~			
Typed or printed name Date:			:		
This collection of information i	a securined by 27 CED 1.6	The information is required to obtain or retain a h	nofit by the n	ublic which is to file (and by the LISPTO to	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:



Express Mail No. EV335611902US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

Jeffery R. Raymond et al.

Application No.

10/624,946

Filed

July 21, 2003

For

3-NITROGEN-6,7-DIOXYGEN STEROIDS AND USES RELATED

THERETO

Examiner

Barbara P. Badio, Ph.D.

Art Unit

1616

Docket No.

480117.407C1

Date

March 11, 2005

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Commissioner for Patents:

RESPONSE TO RESTRICTION REQUIREMENT

In response to the Restriction Requirement, mailed February 11, 2005, reconsideration of the claimed subject matter is hereby requested in view of the following remarks.

Restriction to one of the of the following groups is required under 35 U.S.C. 121:

- Claims 1-10 and 17-53, directed to compounds and pharmaceutical compositions.
- II. Claims 54-63, directed to various methods of using the compounds and pharmaceutical compositions.

Applicants hereby elect, without traverse, Group I as set forth above.

In addition to the restriction requirement, an election of a single compound (or set of compounds) is further required including an exact definition of each substitution on the base molecule wherein a single member at each substituent group or moiety is selected.

Applicants elect, without traverse, the following compound: